Danapha Pharmaceutical JSC (HSTC:DAN) Revenue: ₫ Mil (TTM As of . 20)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HSTC:DAN Danapha Pharmaceutical JSC HSTC:DAN
31 GF Score
Price ₫32,800.00
! 1 Warning Sign
View Full Analysis

What is Danapha Pharmaceutical JSC Revenue?

Danapha Pharmaceutical JSC HSTC:DAN 31 Revenue is ₫ Mil as of . 20. GuruFocus rates HSTC:DAN with a GF Score™ of 31/100. The stock has 1 warning sign investors should review.

Danapha Pharmaceutical JSC's revenue for the six months ended in . 20 was ₫0.00 Mil. Danapha Pharmaceutical JSC does not have enough years/quarters to calculate its revenue for the trailing twelve months (TTM) ended in . 20. Danapha Pharmaceutical JSC's Revenue per Share for the six months ended in . 20 was ₫0.00. Danapha Pharmaceutical JSC does not have enough years/quarters to calculate its Revenue per Share for the trailing twelve months (TTM) ended in . 20.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

Danapha Pharmaceutical JSC  (HSTC:DAN) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.

Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.

Danapha Pharmaceutical JSC Revenue Related Terms

Danapha Pharmaceutical JSC Revenue Historical Data

* Premium members only.

The historical data trend for Danapha Pharmaceutical JSC's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Danapha Pharmaceutical JSC Revenue Chart

Danapha Pharmaceutical JSC Annual Data
Trend
Revenue

Danapha Pharmaceutical JSC Semi-Annual Data
Revenue

HSTC:DAN vs ZTS, UTHR, VTRS: Revenue Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Danapha Pharmaceutical JSC's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Danapha Pharmaceutical JSC Revenue vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Danapha Pharmaceutical JSC's Revenue distribution charts can be found below:

* The bar in red indicates where Danapha Pharmaceutical JSC's Revenue falls into.


HSTC:DAN
31GF Score
Danapha Pharmaceutical JSC HSTC:DAN
Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Danapha Pharmaceutical JSC Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Frequently Asked Questions Learn more about Revenue →
What does a Revenue of ₫ Mil mean?
Danapha Pharmaceutical JSC (HSTC:DAN) has a Revenue of ₫ Mil as of . 20. Revenue is the total amount a company generates as sales through its operations. View historical data on Danapha Pharmaceutical JSC and its competitors.
Is Danapha Pharmaceutical JSC's Revenue too high?
Danapha Pharmaceutical JSC's current Revenue is ₫ Mil. Overall, Danapha Pharmaceutical JSC has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Danapha Pharmaceutical JSC's Revenue compare to ZTS and UTHR?
Danapha Pharmaceutical JSC's Revenue of ₫ Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Drug Manufacturers company?
A good Revenue depends on the Drug Manufacturers industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Danapha Pharmaceutical JSC and its competitors. Danapha Pharmaceutical JSC's current Revenue is ₫ Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Danapha Pharmaceutical JSC stock overvalued right now?
Danapha Pharmaceutical JSC (HSTC:DAN) has a current Revenue of ₫ Mil. The current Revenue is ₫ Mil. Danapha Pharmaceutical JSC's overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Danapha Pharmaceutical JSC (HSTC:DAN), the current Revenue is ₫ Mil as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Danapha Pharmaceutical JSC Business Description

Address 253 Dung Si Thanh Khe, Da Nang, VNM
Danapha Pharmaceutical JSC is a manufacturer of herbal medicine and specific drugs such as central nervous system, neurotonics, anti-diabetics, cardiovascular drug, gastrointestinal and heaptic biliary system with forms such as tablets, capsules, injection, sirup, balm and medicated oil.
31GF Score

Get the complete analysis for HSTC:DAN

Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₫32,800.00
Price